J&J Starts The Year With A Bang With 22 Early-Stage Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The new collaborations cross the company’s diversified business, with an emphasis in pharma on drug discovery and early-stage research in collaboration with biotech and academia.
You may also be interested in...
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: